HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer
Authors
Keywords
HSP90, Pancreatic cancer, Anti-tumor therapy, <em class=EmphasisTypeItalic >Geldanamycin</em>, <em class=EmphasisTypeItalic >Target therapy</em>
Journal
APOPTOSIS
Volume 22, Issue 3, Pages 369-380
Publisher
Springer Nature
Online
2016-11-23
DOI
10.1007/s10495-016-1332-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors
- (2015) Aarif Ahsan et al. NEOPLASIA
- Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells
- (2014) Ye-Lim Ryu et al. CANCER LETTERS
- Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells
- (2012) Che-Hsin Lee et al. BIOCHIMIE
- Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitors in Cancer Therapy: Advances and Perspectives
- (2012) Mengzhu Xue et al. CURRENT PHARMACEUTICAL DESIGN
- Adjuvant and neoadjuvant treatment in pancreatic cancer
- (2012) Marta Herreros-Villanueva WORLD JOURNAL OF GASTROENTEROLOGY
- Metastatic pancreatic cancer: old drugs, new paradigms
- (2011) Thierry Conroy et al. CURRENT OPINION IN ONCOLOGY
- The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
- (2011) Nardin Samuel et al. Nature Reviews Gastroenterology & Hepatology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung
- (2010) Tatyana Kalinina et al. BMC CANCER
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
- (2010) Zacharenia Saridaki WORLD JOURNAL OF GASTROENTEROLOGY
- Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
- (2009) J. Veeken et al. CURRENT CANCER DRUG TARGETS
- Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
- (2008) A. Sawai et al. CANCER RESEARCH
- Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer
- (2008) Ghassan El Maalouf et al. CANCER TREATMENT REVIEWS
- Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
- (2008) X. Cao et al. CLINICAL CANCER RESEARCH
- Resection margins and R1 rates in pancreatic cancer – are we there yet?
- (2008) C S Verbeke HISTOPATHOLOGY
- The Hsp90 Chaperone Machinery
- (2008) Sebastian Karl Wandinger et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
- (2008) Dongweon Song et al. MOLECULAR CANCER THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started